Cargando…
The clinical benefits of immune checkpoint inhibitor for thymic carcinomas ∼experience of single public hospital in Japan∼
Thymic carcinomas is rare and highly aggressive carcinoma. Most patients with them are diagnosed as being at surgically unresectable stages due to it. There are several reports which showed the effect of chemotherapy, however, it is controversial. Recently, immune checkpoint inhibitors have changed...
Autores principales: | Uchida, Naohiro, Fujita, Kohei, Okamura, Misato, Nakatani, Koichi, Mio, Tadashi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250912/ https://www.ncbi.nlm.nih.gov/pubmed/30505679 http://dx.doi.org/10.1016/j.rmcr.2018.11.007 |
Ejemplares similares
-
Development of Mycobacterium avium Complex Lung Disease in Patients With Lung Cancer on Immune Checkpoint Inhibitors
por: Fujita, Kohei, et al.
Publicado: (2020) -
Incidence of Active Tuberculosis in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors
por: Fujita, Kohei, et al.
Publicado: (2020) -
Efficacy and safety of immune checkpoint inhibitors in patients with non‐small cell lung cancer aged 80 years or older
por: Saito, Zentaro, et al.
Publicado: (2021) -
No need to hesitate: immune‐related neutropenia and thrombocytopenia that improved by corticosteroids
por: Kanai, Osamu, et al.
Publicado: (2021) -
Concurrence of nivolumab‐induced interstitial lung disease and cancer invasion
por: Kanai, Osamu, et al.
Publicado: (2017)